INTRODUCTION
Systemic sclerosis (SSc) is an inflammatory fibroproliferative disease whose pathogenesis remains largely elusive. SSc is characterized by the excessive deposition of extracellular matrix (ECM) proteins, particularly collagen, in different organs as a result of dysregulated tissue repair (1) . The deposition of ECM proteins and fibroblast replacement of parenchymal cells occur mainly in the skin and internal organs. This condition exacerbates tissue remodeling and fibrosis, which represent the main pathological manifestations associated with SSc (1) . The clinical manifestations of SSc are heterogeneous and complex, and they have distinctive inflammatory and fibrotic phases, making the disease difficult to treat. Although fibrosis is caused by a series of synergistic events, the dynamic interactions between myofibroblasts, macrophages, and CD4 T cells are thought to be a major component that regulates disease progression (2) . Understanding the cellular and molecular mechanisms that are involved in the interactions between the innate and adaptive immune systems and stromal cells may allow the development of tailored medicines to replace standard of care treatments including antiinflammatory (for example, corticosteroids) and immunosuppressant therapies (for example, methotrexate, mycophenolate mofetil, and cyclophosphamide) that are aimed at minimizing symptoms of SSc.
Studies conducted in animal models and advances in the understanding of the progression of SSc in patients have led to the recognition that T helper (T H ) cells are involved in both the early inflammatory and late fibrotic phases through interaction with differentiated fibroblasts (3, 4) . Mononuclear cells, mainly macrophages and activated effector T H cells, that produce proinflammatory cytokines [for example, interferon- (IFN-) and interleukin-6 (IL-6)] are detectable in the skin during the inflammatory phase of SSc (5-7).
Furthermore, T H cells have been implicated in the fibrotic phase of SSc (8) . The fibroblasts in SSc are involved in both the synthesis and degradation of the ECM, in which matrix metalloproteinase (MMP) molecules (for example, MMP-9 and MMP-12) control the degradative process and facilitate the recruitment of inflammatory cells to the site of injury (9) (10) (11) .
Collagen I is one of the most abundantly expressed proteins in the collagen family in the skin, and its breakdown product, serum C-terminal telopeptide of type I collagen (s-CTX-I), has been found elevated in the serum of patients with SSc compared with healthy controls and correlates with modified Rodnan skin score (mRSS) (12) (13) (14) . Both MMP-9 and MMP-12 are also increased in the serum and tissue of patients with SSc and correlate with the severity of skin fibrosis and vascular damage (10, 11) .
The interaction between dermal fibroblasts and T H cells promotes the up-regulation of the profibrotic cytokines IL-4, IL-13, and transforming growth factor- (TGF-) (6, 15, 16) . The T FH -associated cytokine IL-21 and its cognate, the IL-21 receptor (IL-21R), were also shown to be up-regulated in patients with SSc (17, 18) . These data further support an involvement of T H effector cells and their associated cytokines in the inflammatory and fibrotic phases of SSc. However, the role of T FH -associated IL-21 during the inflammatory and fibrotic phases of the disease is still unclear.
The inducible costimulator (ICOS) protein, one of several costimulatory receptors of the B7/CD28 superfamily, plays an important and nonredundant role in the regulation of adaptive immune responses.
Unlike CD28, which is constitutively expressed on T cells, ICOS is rapidly up-regulated on activated CD4 + effector T cells, and its expression is highest on T follicular helper (T FH ) cells, thus positioning it as a pivotal regulator of humoral responses (19) . ICOS through the binding of its cognate ICOS ligand (ICOSL; B7RP-1) elicits T cell activation, differentiation, and effector responses and controls the expansion of the effector pool size (20) (21) (22) . It plays a critical role in the ontogeny and function of T FH cytokines IL-6 and IL-21 (22) (23) (24) (25) (26) . ICOS + T FH cells have been elevated in patients affected by systemic lupus erythematosus or rheumatoid arthritis, and these cells correlate with disease activity (27) (28) (29) .
Recently, ICOS + T cells were shown to be elevated in the skin of patients with SSc (30, 31) . In addition, in a bleomycin-induced SSc mouse model, ICOS-deficient mice were protected from lung and skin fibrosis relative to wild-type animals (32) . Together, these data suggest that ICOS + T cells may play a role in skin fibrosis in SSc. However, the underlying mechanisms remain poorly defined.
We investigated the involvement of ICOS + T H cells in patients with SSc and their relevance to inflammation and skin fibrosis. We observed that human SSc skin and lesional skin from a graft-versushost disease (GVHD)-SSc mouse model contained a new population of T H cells demarcated as ICOS-bearing T FH -like cells that correlated with skin disease activity. Treatment with an anti-ICOS-depleting monoclonal antibody (MAb) significantly ameliorated disease by blocking the expansion of pathogenic T FH -like cells, thereby providing support for the interplay between ICOS-expressing T H cell subsets and dysregulated fibroblasts.
RESULTS

Patients with SSc have increased frequency of T FH -like cells
One of the main characteristic histopathological findings in SSc skin is dermal fibrosis, which is driven in part by the infiltration of macrophages and activated T lymphocytes (6) . Although it is known that T cells play a key role in SSc, the characterization of these specialized skin T cell subsets remains undefined. To decipher the dermal T cell profiling, we enrolled 28 patients with SSc, who underwent full clinical examination. Lesional skin biopsies were collected for immunoprofiling. Nine of 28 skin biopsies did not pass the quality control check because of poor tissue quality. The baseline demographics and clinical characteristics of patients with SSc are summarized in Tables 1 and 2 . Most of these patients had diffuse SSc with multiple organ system involvement.
A representative photomicrograph of the histological hematoxylin and eosin (H&E) analysis of this patient cohort demonstrated a profound increase in fibrosis and lymphocyte infiltration compared with healthy controls (Fig. 1A) . The expression of transcripts for cd3, cd4, and icos was confirmed to be significantly increased (P < 0.005, P < 0.05, and P < 0.05, respectively) in biopsied lesional skin from patients with SSc ( Fig. 1 , B and C) (30, 31) .
Because the expression of ICOS is associated with the activation and differentiation of T H cells into different lineages, we determined the phenotype and expression pattern of ICOS-associated infiltrating T H cells in the skin of patients with SSc. Gene expression analysis of Bcl6, Tbet, gata3, and rorc demonstrated that skin T cells displayed atypical transcriptional factors profiling ( fig. S1A ). Gene profiling of membrane-expressing T H lineage-specific transcripts was compared between patients with SSc and healthy controls. The expression of chemokine (c-x-c motif), receptor 5 (cxcr5), and programmed cell death 1 (pdcd1, also known as PD-1) was significantly elevated (P < 0.001 and P < 0.005) in SSc skin (Fig. 1C) .
The association of icos with cd3, cd4, cxcr5, and pdcd1 provides a valuable understanding of the putative immune phenotype properties of T H cells in fibrotic SSc skin that are normally associated with T FH cells or their circulating T FH -like relatives. Patients with SSc also expressed significantly elevated il21r mRNA expression (P < 0.0005) in the skin (Fig. 1C) . Correlational analysis of the mRNA expression of pdcd1 and icos, pdcd1 and cxcr5, and icos and cxcr5 showed significant coexpression (P < 0.008, P < 0.05, and P < 0.5 × 10 −5 ) of these genes in lesional skin (Table 3) .
The phenotype of these newly identified T FH -like cells was further investigated by immunohistochemistry (IHC) and multicolor immunofluorescence (IF) staining, which demonstrated the presence of CD4, ICOS, and PD-1 single-positive cells localized throughout the dermis of SSc skin (Fig. 1, E and F) . SSc skin sections demonstrated perivascular staining for CD4, ICOS, and PD-1 by IHC (Fig. 1E) . IF analysis of CD4, ICOS, and PD-1 single-positive cells in SSc skin revealed statistically significant increases in expression (P < 0.005, P < 0.5 × 10 −4 , and P < 0.0005, respectively) compared with healthy control skin (Fig. 1G) . Activated CD4 + ICOS + cells were also elevated in SSc skin (Fig. 1G) .
Analysis of the number of PD-1 + cells versus ICOS + cells, PD-1 + cells versus CD4 + cells, and ICOS + cells versus CD4 + cells also demonstrated significant correlations (P < 0.5 × 10 −6 , P < 0.5 × 10 −5 , and P < 0.5 × 10 −5 , respectively) ( Table 4 ). The coexpression with CD4, ICOS, and PD-1 identified the presence of infiltrated cells in SSc skin that had a cell surface phenotype reminiscent of T FH -like cells (Fig. 1H ). The frequency of T FH -like cells identified by the concomitant expression of ICOS, PD-1, and CD4 was also significantly higher in SSc skin samples (P < 0.001; Fig. 1H ) and represented about 95% of the total activated CD4 + ICOS + T cell population (Fig. 1G ). The involvement of other T H cell subsets was also explored. Quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis demonstrated the presence of T cell-associated transcripts that are characteristic of both T H 1 (Fig. 1D) and T H 2 cell phenotypes ( fig. S1B ). The mRNA expression of the T H 1 transcripts cxcr3 and ifng (Fig. 1D) and T H 2 genes ptgdr2 (crth2) and cxcr4 ( fig. S1B ) was elevated in the skin from patients with SSc. Notably, crth2 and cxcr4 significantly correlated with each other (P < 0.5 × 10 −7 ), whereas both crth2 and cxcr4 negatively correlated with CD4 (Table 5) . Although mRNA expression of ifng correlated with cd4, no significant correla tion was observed between cxcr3 and ifng (P > 0.2) ( 
CXCR5
+ T FH -like cells are associated with fibrosis and elicit myofibroblast differentiation Transcript analysis of molecules that are known to be elevated during active disease in the skin of patients with SSc was assessed. Although mRNAs for inflammatory chemokine (C-C motif) ligand 2 (ccl2) and ligand 5 (ccl5) were modestly increased, vascular cell adhesion molecule 1 (vcam-1) and von Willebrand factor (vwf), which are associated with fibrosis and vasculopathy, were significantly elevated in SSc skin (P < 0.5 × 10 −7 ) ( Fig. 2A) . The correlation of the T FH -like subset-defining molecules with clinical skin score and fibrosis biomarkers was analyzed to determine their association with disease. This analysis showed a statistically significant association between mean mRSS and CD4 (r = 0.61, P < 0.01), ICOS (r = 0.46, P < 0.05), and PD-1 (r = 0.5, P < 0.05; The presence of ECM remodeling fibrotic markers in the serum of patients with SSc was also evaluated to assess ICOS/PD-1/CD4 triple-positive cells with fibrosis biomarkers. A significant correlation was observed between infiltrating ICOS/PD-1/CD4 triple-positive T FH -like cells and s-CTX-I, which represents the degradative byproduct of collagen I (r = 0.54, P < 0.05; Fig. 2B ). Furthermore, VCAM-1 was also significantly up-regulated in patients with SSc and correlated with ICOS/PD-1/CD4 triple-positive T FH -like cells (r = 0.5, P < 0.05; Fig. 2B ). Overall, these data support the implication of T FH -like cells in the fibrotic pathology of SSc.
Myofibroblasts are not commonly found in healthy skin and only arise in response to injury and repair. To evaluate the direct functional impact of the T FH -like cells described above in skin fibrosis, we cultured normal human dermal fibroblasts (NHDFs) with in vitrodifferentiated CD4 + T FH -like cells using a modified T FH polarization protocol (33) . Under polarizing conditions, CD4 + T cells up-regulated CXCR5, ICOS, and PD-1, and a substantial subset coexpressed ICOS and PD-1 (Fig. 2C ). These cells were cocultured with NHDFs at a 1:4 ratio in the presence or absence of suboptimal TGF- and anti-CD3/anti-CD28 beads. After 3 to 4 days in coculture, NHDFs up-regulated the expression of -smooth muscle actin (SMA) within the vimentin-positive cells (Fig. 2D) 
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differentiation of NHDFs was independent of TGF-, which suggests that T FH -like cells can promote SMA up-regulation and myofibroblast differentiation in vitro.
ICOS-expressing T H cells correlate with the clinical manifestation of GVHD-SSc
Because of the observed increase in T FH -like cells in human dermal SSc cells, we investigated the potential involvement of these ICOS + T H cells in skin inflammation and fibrosis. We used the sclerodermatous GVHD (GVHD-SSc) mouse model developed by Ruzek et al. that is characterized by dermal infiltration of activated T cells and macrophages, resulting in skin remodeling and dermal fibrosis (fig. S2, A and B) (34) . We confirmed the accumulation and expansion of CD3 + T cells and F4/80 + macrophages in the thickened dermis that coincided with the peak manifestation of skin pathology ( fig. S2 , C, D, and F). These data support previous findings regarding the correlation between skin T lymphocytes and the initiation and progression of GVHD-SSc cutaneous fibrosis. Tables 1 and 2 . P value was determined by unpaired t test (*P < 0.05, **P < 0.005, ***P < 0.0005, and ****P < 0.00005).
On the basis of the finding that T lymphocytes were associated with the onset of GVHD-SSc dermal fibrosis, we further characterized their phenotype, including expression of costimulatory molecules. mRNA assessment on lesional skin from GVHD-SSc mice was conducted at days 7, 14, 21, and 28. A 20-fold increase in the expression of cd3e was observed in GVHD-SSc mice compared with syngeneic mice starting on day 7 and lasting through day 28 ( Fig. 3A ). This finding was striking when compared with the modest twofold increase in macrophage-associated EGF module-containing, mucin-like, hormone receptor-like 1 (emr1 or f4/80) expression (Fig. 3A) . The expression of f4/80 increased fourfold by day 14 before dropping to less than twofold by day 28. This observation suggests that CD3 + T cells are the major lymphocyte population involved during the onset and maintenance of cutaneous GVHD-SSc disease.
We further assessed the mRNA expression of CD4, along with T cell costimulatory and inhibitory molecules icos, cd28, and pdcd1. The expression of these genes was substantially elevated more than fivefold as early as day 7 and remained elevated throughout the disease duration in GVHD-SSc mice (Fig. 3A) . Other immune cells, including cd19 B cells, nk1-2/nkp46 natural killer cells, and cd1d natural killer T cells, with the exception of cd11c dendritic cells (DCs), were not considerably elevated as the CD3 + CD4
+ T cell compartment ( fig. S2E ). Overall, the data indicate that CD4 + T cells and their associated costimulatory and inhibitory molecules may play a central role during the initial inflammation and disease progression of cutaneous fibrosis of GVHD-SSc mice. Multiparameter fluorescence-activated cell sorting (FACS) analysis showed that about 60% of the lymphocytes in the lesional skin of GVHD-SSc mice were CD3 + T cells. Of these, more than 30% were CD4 + T cells, most of which (~70%) displayed a CD44 + CD62L − effector phenotype (Fig. 3B ). About 60% of the effector CD4 + T cell also expressed ICOS, confirming the gene expression data and underlining their potential role in the progression of GVHD-SSc (Fig. 3B) The total number of CD4 + T cells in GVHD-SSc mice was 30-fold greater than in the control group by day 8 and 40-fold greater by day 28 (Fig. 3C) . Among the effector CD4 + cells (CD44 hi CD62L lo/neg ), ICOS + T cells were substantially elevated (about 80-fold) (Fig. 3C ). The frequency of skin F4/80 macrophages increased threefold from day 8 until the end of the study ( fig. S2F) .
We next quantified the T H cell subsets in the lesional skin of GVHD-SSc mice and observed that T FH -and T H 1-like cell subsets were greatly expanded compared with the control group (Fig. 3, C  to F) . This also included a 30-fold expansion of ICOS + cells within the T H 1 subset (Fig. 3C) . S2H ). The transcription factor profiling demonstrates an atypical heterogeneous T H cell environment. It should be noted that the Foxp3 + regulatory T cell population was expanded throughout the onset and progression of the GVHD murine SSc, although the expression of ICOS remained unaltered within this subset ( fig. S2I ). These data further confirm the heterogeneity and potential plasticity of the inflammatory CD4 + T cells in the skin of GVHD-SSc mice.
ICOS + T cells drive GVHD-induced fibrosis The prominence of CD4
+ ICOS + T cells in SSc and in the skin of GVHD-SSc mice may suggest involvement of these cells in inflammation, fibrosis, or both. To test this hypothesis, we treated GVHD-SSc mice from day 12 to allow cell engraftment and disease initiation with a glycoengineered immunoglobulin G1 (IgG1) anti-ICOS MAb with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity (anti-ICOS-aFuc MAb; table S2). Anti-ICOS-aFuc MAb elicited effective depletion of ICOS-expressing T cells, as demonstrated in vitro by the ADCC assay and in vivo after injection into GVHD-SSc mice ( fig. S3, A and B) . The administration of the anti-ICOS-aFuc MAb in GVHD mice resulted in inhibition of disease manifestation, as indicated by the in-life clinical scoring as early as day 17 and for the entire duration of the study (Fig. 4A) . Disease severity, along with incidence of dermal lesions and alopecia, was reduced compared with the control groups. Unlike the depleting anti-ICOS-aFuc MAb, a blocking anti-ICOS MAb (anti-ICOS-TM) that share the Fab region directed against the ligand-binding domain of ICOS failed to effectively block disease progression (Fig. 4A ). This occurred although the anti-ICOS-TM blockade MAb suppressed germinal center responses in the spleen ( fig. S4, A and B) . Therefore, the in-life mean clinical score data indicated that depletion of ICOS-expressing T cells can control GVHD-SSc to a much greater degree than simply blocking ICOS-ICOSL interactions.
To assess the impact of the anti-ICOS-aFuc MAb on lymphocyte infiltration, tissue remodeling, and fibrosis, we assessed dorsal skin from the different treatment animal groups by H&E and Masson's trichrome (MT) staining. Treatment with anti-ICOS-aFuc MAb resulted in substantially reduced mononuclear cells infiltration, collagen deposition, and thickening of the skin (Fig. 4, B and C) . IHC analysis also confirmed the reduction of CD3 + T cells and F4/80 + macrophages in the skin of anti-ICOS-aFuc MAb-treated mice ( fig. S4, C and D) . Despite controlling early disease manifestation, the blocking anti-ICOS-TM MAb failed to control the histological characteristics of the disease, including infiltrating leukocytes, dermal thickening, and fibrosis, when compared with the depleting anti-ICOS-aFuc MAb (Fig. 4 , B and C).
To further explore the effects of depletion of ICOS + T cells, we performed FACS analysis of T cell subsets isolated from lesional skin. Treatment with anti-ICOS-aFuc MAb inhibited the expansion of total CD4 + and effector CD4 + ICOS + T cells threefold or greater when compared with the isotype MAb-treated group (Fig. 4D) . Furthermore, anti-ICOS-aFuc MAb treatment depleted the ICOS-expressing T FH -like cells and the T H 1-like cells (45-and 12-fold reduction, respectively) (Fig. 4D) . These results collectively confirmed the key contribution of ICOS-bearing T H cell subsets to the initiation and progression of skin inflammation and dermal fibrosis.
ICOS + T H cells contribute to the proinflammatory and profibrotic conditions in GVHD-SSc
On the basis of the considerable improvement of GVHD-SSc after treatment with anti-ICOS-aFuc MAb, we examined the correlation between ICOS + T H cell depletion and the expression of profibrotic cytokines and proinflammatory factors that contribute to inflammation and cutaneous fibrosis. Enzyme-linked immunospot (ELISpot) assessment demonstrated a significant increase (P < 0.05) in the number of IFN--, IL-4-, and IL-21-producing T H and T FH -like cells in GVHDSSc mice (Fig. 4E) . However, the frequency of IL-13-associated T H 2 cytokine-producing cells remained unchanged in GVHD-SSc mice compared with syngeneic animals.
The presence of these proinflammatory and profibrotic cytokines in T H and T FH -like subsets was also confirmed by intracellular flow cytometry assays using sorted CD4 + effector skin T cells ( fig. S5 ). The data demonstrated that treatment with the anti-ICOS-aFuc MAb inhibited the proinflammatory IFN-, as well as IL-4 and IL-21 expression, whereas the production of the profibrotic cytokine IL-13 in the skin of GVHD-SSc mice was not impacted by ICOS-aFuc MAb treatment (Fig. 4E) .
IL-21, one of the prominent T FH -associated cytokines, has been linked to fibrosis (17, 18, 35) . The expression of IL-21 transcript was significantly increased (P < 0.005) in the skin from GVHD mice and almost completely inhibited by anti-ICOS-aFuc MAb treatment (Fig. 5A ). This finding is in alignment with the observed reduction in the numbers of skin IL-21-producing lymphocytes (Fig. 4E) . These data confirmed that treatment with ICOS-depleting MAb was responsible for the prominent inhibition of T H 1-and T FH -like cytokines, including IL-21, which could be one of the key drivers of cutaneous GVHD-SSc.
To further assess the effects of depletion of ICOS + T H cells, we measured the expression of a broader array of mediators involved in inflammation and fibrosis by quantitative RT-PCR and multianalyte profiling of soluble serum proteins. Molecules involved in inflammation and lymphocyte recruitment, such as monocyte chemotactic protein-1 (mcp-1) and regulated on activation normal T cell expressed and secreted (rantes), were significantly induced (P < 0.05) under GVHD conditions as early as day 12 ( fig. S6A ) and subsequently reduced 5-to 20-fold upon the depletion of ICOS-expressing T cells (Fig. 4,  F and G) . Similarly, the serum expression of other inflammatory mediators, such as IL-6 and MCP-5, was up-regulated in GVHD-SSc mice and profoundly reduced upon the removal of ICOS-expressing T cells (Fig. 4G and fig. S6 , B and C).
Vascular alterations are a major component of disease manifestation in SSc (34, 36) . Serum expression of vasculopathy mediators, such as endothelin-1 and vWF, was increased in GVHD-SSc mice (Fig. 4G and  fig. S6D ) and significantly reduced (P < 0.0005) in mice treated with anti-ICOS-aFuc MAb. Finally, fibrotic mediators, such as VCAM-1 and MMP-9, were markedly elevated in GVHD-SSc mice (Fig. 4G and  fig. S6E ), and their expression subsequently declined (P < 0.0005) after the depletion of ICOS-expressing T cells.
Collectively, these observations demonstrated that the deletion of ICOS + T H cells can effectively block GVHD disease manifestations and provide protection from inflammation and fibrosis. Blocking the interaction of ICOS with its ligand was not sufficient to prevent skin pathology, and this finding further emphasizes the direct involvement of ICOS + T effector cells in skin inflammation and fibrosis.
Anti-ICOS depleting MAb ameliorates GVHD-SSc by perturbing the interaction between fibroblasts and T H cells
Microarray gene expression analysis conducted on GVHD-SSc skin showed that the expression of several MMPs were significantly increased between day 21 and day 28 compared with the syngeneic control animals (37) . Quantitative RT-PCR analysis confirmed a significant increase (P < 0.05) in the expression of mmp-12 in GVHD-SSc mice and its subsequent significant inhibition (P < 0.05) in response to anti-ICOS-depleting MAb (Fig. 5A) . Likewise, the expression of il21, described previously, and il21r transcript was both elevated in GVHD-SSc mice and significantly inhibited (P < 0.0005) by treatment with anti-ICOS-depleting MAb (Fig. 5A ). In addition, the expression of IL-21R on fibroblasts (CD3 To investigate the relevance of the IL-21/IL-21R axis in the crosstalk between ICOS + T FH -like cells and stromal cells involved in skin fibrosis, we isolated dorsal dermal fibroblasts from GVHD-SSc and syngeneic mice. Analysis of the supernatant collected from GVHD fibroblast cultures showed that MMP-12 expression increased almost twofold compared to the control graft and was undetectable in the ICOS-aFuc MAb treatment group (P < 0.05; Fig. 5C ). To assess the impact of IL-21 as a profibrotic cytokine on MMP-12 biology, we stimulated GVHD-derived skin fibroblasts with recombinant IL-21. TaqMan RT-PCR analysis demonstrated that IL-21 induced significant mRNA expression of mmp-12 and il21r (P < 0.05) (Fig. 5, D and E). These data suggest that IL-21-producing ICOS + T FH -like cells could cooperate with dermal fibroblasts in a profibrotic loop that involves the expression of IL-21R and MMP-12 production via IL-21.
IL-21 neutralization protects from skin fibrosis in GVHD-SSc mice
To explore a direct link between IL-21 and disease pathogenesis, we conducted IL-21 neutralization studies in GVHD-SSc mouse model. The neutralization of IL-21 (IL-21R-Fc was administered starting -differentiated myofibroblasts were determined by flow cytometry after direct coculture assay of in vitro-differentiated T FH -like cells with normal human dermal fibroblasts (NHDFs) at a T cell-to-fibroblast ratio of 1:4 in the presence or absence of suboptimal transforming growth factor- (TGF-) and anti-CD3/anti-CD28 antibodies (FMO, fluorescence minus one). All correlations were carried out using Spearman's correlation analyses (n = 19 patients with SSc). Data represent two independent experiments. P value was determined by unpaired t test (*P < 0.05, ***P < 0.0005, and ****P < 0.00005).
at day −1, three times per week) resulted in significant reductions (P < 0.05) in skin inflammation and fibrosis, as determined by disease clinical and histological scores (Fig. 6, A and B) . H&E and MT staining of dorsal skin demonstrated that IL-21 neutralization resulted in the reduction of infiltrating mononuclear cells, skin remodeling, and dermal fibrosis compared with control mice (Fig. 6C) . These results support the involvement of IL-21 in skin fibrosis and disease pathogenesis mediated by ICOS-expressing T FH -like cells. Notably, IL-21 neutralization also functionally affected germinal center B cells in the spleen, as measured by a reduction in GL-7 + CD95 hi -expressing B cells (Fig. 6D) . TaqMan RT-PCR analysis of genes associated with T FH -like markers (cd4, icos, pdcd1, and cxcr5), fibrotic markers [mmp-12,  mmp-13, mmp-1a, tgf-1, fibroblast growth factor 15 (fg f 15) , and vcam-1], and inflammatory mediators (ccl5, ccl2, and il6) demonstrated that IL-21 modulates molecules involved with the pathogenesis of GVHD-SSc (Fig. 6E and table S3 ). IL-21 neutralization resulted in statistically significant reductions (P < 0.005) in the T FH -associated markers cd4, icos, and pd-1 while demonstrating a trend toward reduced cxcr5 (Fig. 6E) . The fibrotic genes mmp-12, mmp-13, mmp-1a, tgf-1, fgf15, and vcam-1 were all profoundly reduced in the IL-21R-Fctreated cohort (Fig. 6E) , supporting the histological finding showing reduced MT staining and less fibrosis (Fig. 6C) . Consistent with our previous findings, inflammatory mediators ccl5, ccl2, and il6 were also affected by IL-21 neutralization, resulting in their significant reduction (P < 0.005; Fig. 6E ). Collectively, this result demonstrates that IL-21 neutralization can affect immune cells and their associated factors that are involved in driving disease pathogenesis and skin fibrosis in the GVHD-SSc mouse model. ). Subsets were compared with syngeneic controls. Data represents three independent experiments. P value was determined by unpaired t test (**P < 0.005 and ***P < 0.0005). Total RNA samples isolated from skins of all treatment groups were subjected to TaqMan gene expression analysis against a selected gene set. Data were expressed as fold expression changes compared with syngeneic group. P value for gene expression data was calculated using one-way analysis of variance (ANOVA). (G) Serum samples from each treatment group were assessed for selected molecules using the multiplexed immunoassay profiling platform. Data are graphed on a log 2 scale to illustrate the fold change. Data represent three independent experiments. P value was determined by unpaired t test, and the ANOVA model was used to estimate the mean differences in the log 2 scale of the protein concentrations (*P < 0.05, **P < 0.005, and ***P < 0.0005). ns, not significant; vWF, von Willebrand factor. the same cells. This was further supported by the coexpression of CD4, ICOS, and PD-1 in lesional skin using confocal microscopy. However, this associative trend was not consistent among of the evaluated T H 1 and T H 2 transcripts, indicating a possible predominance of the T FH -like cells and identifying them as a distinctive lineage involved in fibrosis.
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Although the expression of ICOS has been recently demonstrated in SSc skin (30, 31) , our results associated its expression with T FH -like and IFN--producing cells and demonstrate that this population is present in human SSc skin and in murine GVHD-SSc. T FH -like cells of a similar phenotype were also recently described in renal biopsies of patients with lupus nephritis and were inferred to contribute in situ to inflammation (38) . Likewise, these T FH -like cells were observed in the circulation of patients with systemic lupus erythematosus and correlated with elevated autoantibody and disease activity, which is indicative of their relationship to disease pathogenesis (27) . These T FH -like cells may also be linked to T H 1-driven pathology, as evidenced by recent data that support the development of T H 1 cells via a pathway that includes cellular transition by a T FH route (39) . Such plasticity may create a phenotypic heterogeneous environment between T H 1 and T FH , where Tbet repressed conventional T FH functionality (39) . In addition, IL-21 + IFN- + double-secreting cells that were Bcl-6-negative and coexpressed ICOS were observed in a Plasmodium chabaudi infection model and found to be involved in parasite clearance (40) . It would be interesting to explore this finding in future SSc studies.
The T FH -like cells identified in the skin of patients with SSc may serve a different and intriguing fibrosis function. This is supported by their correlation with mRSS and CTX-I, as well as their direct impact on myofibroblast differentiation, which is supportive of their abilities to drive a fibrotic mechanism. Furthermore, SSc skin T FH -like cells correlated with serum VCAM-1, a biomarker for vascular damage that is a key event in fibrosis (41) . Despite the limitation of our small sample size used in this study, the correlation seen between T FH -like cells and these parameters that reflect active disease was striking and identifies a causal relationship linking them to a role in disease pathogenesis. Most recently, T cell activation pathways and collagen accumulation that have been associated with a range of profibrotic molecules, such as CTX-I, N-terminal type III procollagen peptide, and MMP-derived degradative neoepitopes of type III collagen, were used to monitor the downstream effect of type I IFN receptor blockade in patients with SSc (14) . Our finding further associates a subset of skin-infiltrating T cells with fibrotic involvement in SSc. Moreover, the impact of their depletion on molecules (C) MMP-12 expression in supernatants from syngeneic or GVHD-SSc skin fibroblasts cultured for 48 hours was determined by enzymelinked immunosorbent assay. (D and E) Single-cell suspension was prepared from digested skin of syngeneic and GVHD-SSc mice. Cells were cultured for 12 days with two passages to yield confluent fibroblasts. Fibroblasts isolated from either syngeneic or GVHD-SSc animals were stimulated with recombinant IL-21 for 18 hours, followed by RNA isolation and real-time reverse transcription polymerase chain reaction analysis for IL-21R and MMP-12. Data are representative of two to three independent experiments. P value was determined by unpaired t test (*P < 0.05, **P < 0.005, and ***P < 0.0005).
associated with inflammation (42), vasculopathy (9), and fibrosis (11) in SSc suggests that ICOS-bearing T H 1 and T FH -like cells may be involved during the early inflammatory and subsequent fibrotic phases of the disease.
The presence of T FH -like cells in the lesional skin of GVHD-SSc is profound and raises important questions about their infiltration and expansion. Although the maintenance of T FH cells in germinal centers requires B cells , interactions between DCs and naive T H cells are critical to initiate the T FH cell program (43, 44) . This was supported in studies that have shown that in the context of abundant and prolonged antigen presentation, DCs are the favored drivers of T FH cell differentiation, whereas B cells function in a more antigen-stringent environment (43) . It is possible that DC is the major player in the generation of T FH -like cells in GVHD-SSc mice. In addition to their role in costimulatory pathways involving CD28/B7, ICOS/ICOSL, and OX40/OX40L, DCderived IL-6 and IL-21 are required for the differentiation of T FH cells (26, 45, 46) . Elevated IL-6 in patients with SSc correlated with increased skin thickness, fibrosis, and differentiation of IL-4-producing T H 2 cells (47) (48) (49) . In addition to IL-6 and IL-21, IFN- mRNA and protein were also elevated in SSc and GVHD-SSc environments and hi gate. (E) TaqMan gene expression assay was conducted on RNA samples isolated from the skins of all treatment groups. Data were expressed as fold expression change relative to the syngeneic group. Data represent two independent experiments. P value was determined by unpaired t test (*P < 0.05, **P < 0.005, and ***P < 0.0005).
may also contribute to the development and expansion of dermal T FH -like cells. It has been shown that heightened IFN- signaling contributed to the initial expansion of T FH cells by up-regulating the expression of . Together, these data provide a likely mechanism for the generation and expansion of T FH -like cells. In addition to the requirement for the formation of T FH cells, IL-21 is a major cytokine produced by T FH cells that drives the activation of several lymphocyte populations and various nonimmune cells. Recent reports have implicated IL-21 under several autoimmune conditions, including skin inflammation (psoriasis) and SSc dermal fibrosis (17, 51) . Most recently, IL-21-producing CD8 cytolytic-2 T cells have been shown to elicit lung fibrosis in a bleomycin sterile lung injury model, further supporting its functionality beyond regulation of B cell responses (52) . In a related study, synovial fluid-sorted CD4 + IL-21 + cells could induce the secretion of MMP-1 and MMP-3 by a fibroblast-like synoviocyte cell that promoted inflammation and joint pathology in rheumatoid arthritis patients, further supporting other nonclassic roles for cells with this phenotype (53) . Signaling of IL-21 requires the interaction with IL-21R whose expression was elevated in the patient cohort investigated in this study and in another published population (51) . Moreover, our study suggests that the IL-21 signaling axis was active at the stromal level to influence dermal remodeling by modulating MMPs and fibroblast growth factor in a profibrotic loop that involves the expression of IL-21R. The elimination of IL-21-producing ICOS + T FH -like cells or neutralization of IL-21 similarly inhibited molecules, such as IFN-, IL-6, TGF-, FGF15, VCAM, and MMPs, that are implicated in both the inflammatory and profibrotic phases characterizing disease pathogenesis seen in GVHD-SSc. These data provide a link between the IL-21/IL-21R axis and fibrosis and further implicate IL-21-producing T FH -like cells in disease pathology. Several cytokines, including IL-1, tumor necrosis factor-, and MCP-1, have been correlated with increased expression of IL-21R in the skin from patients with SSc (17) . However, none of these cytokines was directly involved in the regulation of IL-21 and IL-21R expression by fibroblasts.
The blockade of the ICOS/ICOSL axis was not sufficient to control the expansion of skin-infiltrating T H 1-and T FH -like cells and the production of proinflammatory and profibrotic cytokines. Such behavior could not have been attributed to a lack of pharmacological activity by the MAb because both the depleting and blocking ICOS MAbs showed similar inhibition of IgG expression and T FH celldependent B cell activation of and germinal center B cell formation in the secondary lymphoid tissues of GVHD-SSc mice. This inability may arise, in part, from the activation of alternative pathways, such as the CD28-B7, CD40-CD40L, or 4-1BB-4-1BBL axes, which are expected to be activated in such a highly inflamed environment (54) . IL-13 has been shown to be associated with human SSc pathogenesis, correlated with the inflammatory subtype of SSc and most recently implicated as a driver of fibrosis in a similar GVHD-SSc pathological environment (55, 56) . Although the GVHD-SSc model we used focused on the functional consequences of ICOS-expressing T cells at the peak fibrotic window (day 28), Greenblatt et al. characterized elevated IL-13 expression at around day 14, which is more reflective of an inflammatory phase that may be regulated by a different cytokine profile (56) . The depletion of ICOS + T H cells affected the number of macrophages but not the number of IL-13-producing T cells. This may suggest that other IL-13-producing cells are at play in our model (18, 57) . Although we did not evaluate the expression of IL-13 at day 14, serum analysis at day 12 revealed the presence of a diverse array of proinflammatory factors. Despite these differences, both studies are in agreement that CCL2 is up-regulated and that CD4 + T cells are key sources of profibrotic cytokines.
There are some limitations to our study that should be highlighted. First, the size of our SSc patient cohort is small and did not allow for stratification based on medication. The size may have also affected the statistical power of the study that could have supported alternative interpretation of the data. Despite this, our conclusion and hypothesis on the involvement of T FH -like cells in SSc were well supported by statistically significant associations of these cells with molecules implicated in disease pathology. Second, the size of the patient's biopsies was limited and did not allow for the investigation of T cells eluted from patient's skin. Future work would be required to incorporate this approach and compare the immune infiltrates in the lesional and nonlesional skin from patients with SSc. Third, there may be some limitation in the GVHD-SSc mouse model that may not have completely mimics the human disease. Finally, the fact that the use of an anti-ICOS-depleting reagent does not specifically target T FH -like cells is well noted; however, no reagents are currently available to selectively target T FH -like or other T H subsets that would allow for a robust pharmacodynamic assessment of their direct contribution to disease pathology in mouse models. To that end, the anti-ICOS MAb used in our study is neither T FH -like cell-specific nor a global T cell-depleting agent but allowed us to effectively assess ICOS + T H cells. Collectively, the data identify an important interplay between infiltrating ICOS + T cell subsets and dysregulated fibroblasts, demonstrated by profoundly reduced inflammation and fibrosis in GVHDSSc after the removal of ICOS + T cells. The increased frequency of ICOS-expressing T FH -like cells have been described in several autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and inclusion body myositis (27) (28) (29) (58) (59) (60) (61) . Here, we expanded the role of ICOS + T cells, including T FH -like cells, to SScassociated fibrosis as a result of their positive correlation with disease score and ECM remodeling molecules that are related to disease pathogenesis. Although the etiology of most autoimmune diseases is still largely unknown, the results presented here further support the notion that ICOS may be an attractive therapeutic target for the treatment of fibroproliferative disorders.
MATERIALS AND METHODS
Study design
GVHD-SSc
The study was initiated to evaluate the contribution of ICOS + T H cells in patients with SSc and in a murine model that recapitulate key characteristic features of the human disease. The significance of ICOS + T H cells to the pathological manifestation of inflammation and skin fibrosis was incorporated in this study to support the validity of testing specific therapeutics. The GVHD-SSc model generated by the injection of 8-to 10-week-old female spleen cells from B10.D2 mice into 8-to 10-week-old Rag2-deficient BALB/c female mice shared characteristic feature with the human disease inclusive of immune inflammation, dermal fibrosis, and vasculopathy. GVHD-SSc animals were randomly assigned to control [phosphate-buffered saline (PBS), isotype control MAb, or control Fc) or treatment groups (ICOS-TM or ICOS-aFuc MAb and IL-21R-Fc). Sample size and disease end time points were selected on the basis of previous studies. In-life clinical score was performed in a blinded fashion. Image analysis processing on skin sections were blind-graded by a board-certified pathologist in a blinded fashion. Flow cytometry on the lesional skin of GVHD-SSc mice, ELISpot assay, and TaqMan gene assessment were incorporated to quantify and define skin-infiltrating immune cells. The data analysis on treatment groups was performed by a blinded statistician. Animal experiments were performed in accordance with animal protocols approved by MedImmune Animal Care and Use Committee in compliance with Association for Assessment and Accreditation of Laboratory Animal Care guidelines.
Scleroderma patients
The human study was conducted in accordance with the Declaration of Helsinki, International Council for Harmonization Guidance for Good Clinical Practice, and all local laws. The ethics committee from each participating hospital approved the study protocol and all amendments. All subjects provided written informed consent before study participation. Subjects (males and females, ≥18 years of age) that fulfill the American Rheumatism Association (American College of Rheumatology) preliminary classification criteria for SSc with at least moderate skin thickening (score of at least 2 by mRSS) in at least one area suitable for biopsy (that is, arms, legs, or trunk) were included. Patients who received any investigational drug therapy including depleting and nondepleting T and B biologic therapies before the study (or within five half-lives of ingestion, whichever is longer) and patients with any opportunistic infection or serious infection or with history of severe viral infection and positive tests for hepatitis A, B, and C were also excluded. Quantitative confocal IF microscopy and TaqMan gene profile were incorporated to correlate findings with fibrosis markers in the disease cohort.
Patients and clinical assessment
Lesional skin biopsies were obtained from 19 of 28 enrolled adult patients with SSc who had at least moderate skin thickening and fulfilled the American College of Rheumatology criteria for SSc ( Table 1) . The study protocol was reviewed and approved by the Institutional Review Board or independent ethics committee of each participating center before study initiation. Written informed consent was obtained from each participant before study entry.
Eligible patients were not treated with any MAb therapy at any time and did not receive more than 20 mg/day of leflunomide within the 6 months before the study. Doses of certain concomitant medica tions, such as cyclophosphamide, prednisone, methotrexate, and mycophenolate mofetil, were also reduced within the 21 days before the study.
No stratification of patient outcomes with medication was reported because of the size of the clinical cohort. In addition, the patients' medical histories demonstrated the involvement of other organ systems, including cardiovascular, gastrointestinal, respiratory, musculoskeletal, endocrine, immunological, neurological, and urogenital systems. However, no correlation was made with skin manifestation or disease duration because of the small sample size and the limited scope of this work. The dermatological features captured in patients' medical histories included alopecia areata, chronic dry skin, proximal skin thickening, and recurrent rashes. The antinuclear antibody test data, summarized in Table 1 , were not segregated into individual tests to differentiate anti-RNA polymerase III antibodies from anticentromere antibodies for prognostic determination because this was outside the scope of our study. Biopsies from 20 healthy adult volunteers were used as controls (Table 2) . Primary data are reported in table S4.
Statistical analysis
The analysis of variance (ANOVA) model was used to estimate the mean differences in the log 2 scale of the protein concentrations among animal groups; a P value of less than 0.05 was considered statistically significant. Statistics software (SAS version 9.1, SAS Institute Inc.) was used for statistical analysis. Additional statistical analysis was performed using GraphPad Prism 6 for flow cytometric, clinical scoring, ELISpot, and gene expression data using one-way ANOVA or unpaired t test (two-tailed). Correlation analyses were carried out using Pearson's or Spearman correlation coefficients, and P values of less than 0.05 were considered statistically significant.
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